Literature DB >> 30332349

Psychiatric and Substance Use Comorbidity in Treatment-Seeking Injection Opioid Users Referred From Syringe Exchange.

Michael Kidorf1, Stephanie Solazzo1, Haijuan Yan1, Robert K Brooner1.   

Abstract

OBJECTIVE: The present study evaluated rates of co-occurring current psychiatric and substance use disorders in a sample of opioid-dependent treatment-seeking injection drug users referred from syringe exchange.
METHODS: Participants (N = 208) completed the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-R to assess current (within the past year) psychiatric and substance use disorders and the two most commonly diagnosed personality disorders (antisocial and borderline personality disorders).
RESULTS: Forty-eight percent of the sample had a current Axis I psychiatric disorder, and 67% had a co-occurring current substance use disorder. Posttraumatic stress disorder (21%), major depression (17%), and bipolar I (12%) were the most prevalent Axis I psychiatric disorders, and cocaine use disorder (53%) was the most commonly co-occurring substance use disorder. Women were more likely to have diagnoses of most anxiety disorders and less likely to have diagnoses of alcohol use disorder or antisocial personality disorder. The presence of a personality disorder was associated with higher rates of cocaine and sedative use disorder.
CONCLUSIONS: Findings suggest the importance of evaluating and treating co-occurring psychiatric and substance use disorders in the treatment of injection drug users with opioid dependence.

Entities:  

Keywords:  agonist treatment; gender; opioid dependence; syringe exchange

Mesh:

Year:  2018        PMID: 30332349     DOI: 10.1080/15504263.2018.1510148

Source DB:  PubMed          Journal:  J Dual Diagn        ISSN: 1550-4271


  9 in total

Review 1.  Comorbidity of opioid-related and anxiety-related symptoms and disorders.

Authors:  Kirsten J Langdon; Kathrine Dove; Susan Ramsey
Journal:  Curr Opin Psychol       Date:  2019-01-04

2.  Accelerating the Pace of Science: Improving Parenting Practices in Parents with Opioid Use Disorder.

Authors:  Camille C Cioffi; Leslie D Leve; John R Seeley
Journal:  Parent Sci Pract       Date:  2019-06-17

3.  Mechanisms and Clinical Features of Co-occurring Opioid and Nicotine Use.

Authors:  Sarah D Lichenstein; Yasmin Zakiniaeiz; Sarah W Yip; Kathleen A Garrison
Journal:  Curr Addict Rep       Date:  2019-04-27

4.  Tramadol and Codeine Stacking/Boosting Dose Exposure Induced Neurotoxic Behaviors, Oxidative Stress, Mitochondrial Dysfunction, and Neurotoxic Genes in Adolescent Mice.

Authors:  I O Ishola; S U Eneanya; O R Folarin; I O Awogbindin; A J Abosi; J O Olopade; N U Okubadejo
Journal:  Neurotox Res       Date:  2022-07-13       Impact factor: 3.978

5.  Sexual-risk reduction following the referral of syringe exchange registrants to methadone maintenance: Impact of gender and drug use.

Authors:  Michael Kidorf; Robert K Brooner; Haijuan Yan; Jessica Peirce
Journal:  J Subst Abuse Treat       Date:  2021-01-09

6.  Prevalence of Mental Health Disorders among Individuals Enrolled in an Emergency Response Program for Treatment of Opioid Use Disorder.

Authors:  Christine Bakos-Block; James R Langabeer; Andrea Yatsco; Marylou Cardenas-Turanzas; Tiffany Champagne-Langabeer
Journal:  Subst Abuse       Date:  2020-12-21

7.  Modeling Stimulant and Opioid Co-use in Rats Provided Concurrent Access to Methamphetamine and Fentanyl.

Authors:  Robert W Seaman; Chris Lordson; Gregory T Collins
Journal:  Front Psychiatry       Date:  2022-02-14       Impact factor: 4.157

8.  Healthcare seeking among Swedish patients in opioid substitution treatment - a mixed methods study on barriers and facilitators.

Authors:  Katja Troberg; Karin Lundqvist; Helena Hansson; Anders Håkansson; Disa Dahlman
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-02-05

9.  Impact of Morphine Dependence and Withdrawal on the Reinforcing Effectiveness of Fentanyl, Cocaine, and Methamphetamine in Rats.

Authors:  Robert W Seaman; Gregory T Collins
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.